Suzuki K, Ichinose Y, Hashimoto K, Matsumoto K, Suzuki T, Imai K, Yamanaka H
Department of Urology, Gunma University School of Medicine.
Hinyokika Kiyo. 1990 May;36(5):557-60.
Transrectal ultrasonotomography is useful in following patients with benign prostatic hypertrophy, because prostatic shape and weight are precisely assumed. We studied the effect of chlormadinone acetate (CMA) on benign prostatic hypertrophy. CMA (50 mg/day) was administered to 30 patients with benign prostatic hypertrophy. Weight reduction over 10% of the gland was noticed in 24 cases (80%). Mictional conditions were improved in 70% subjectively and in 71.4% objectively. However, the number of nocturia decreased in only 18.9%. Reduction rate of the weight was unrelated with the weight of prostate before administration of CMA. Duration of administration of CMA and the reduction rate were estimated. There was no definite difference in reduction rate for the first 15 months, but there was a slightly high reduction rate after administration of CMA for more than 24 months. In 3 cases, the shape and weight of prostate were studied after discontinuation of CMA. The size of prostate showed a tendency to increase gradually.
经直肠超声断层扫描对于跟踪前列腺增生患者很有用，因为可以精确推测前列腺的形状和重量。我们研究了醋酸氯地孕酮（CMA）对前列腺增生的影响。对30例前列腺增生患者给予CMA（50毫克/天）。24例（80%）患者的腺体重量减轻超过10%。主观上70%的患者排尿情况得到改善，客观上71.4%的患者排尿情况得到改善。然而，夜尿次数仅减少了18.9%。体重减轻率与服用CMA前前列腺的重量无关。评估了CMA的给药持续时间和减轻率。在最初15个月内减轻率没有明显差异，但服用CMA超过24个月后减轻率略高。3例患者在停用CMA后研究了前列腺的形状和重量。前列腺大小有逐渐增大的趋势。
